MktsMarkets

NextCure, Inc.
NASDAQ: NXTCKey statistics
NXTC News
Stories mentioning NXTC from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 6,834 | 6,800 | 6,136 | 24,091 | 7,896 | 8,902 | 8,770 | 12,418 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 10,105 | 9,757 | 8,945 | 27,292 | 11,622 | 12,455 | 12,495 | 16,494 |
| Operating Income (Loss) | (10,105) | (9,757) | (8,945) | (27,292) | (11,622) | (12,455) | (12,495) | (16,494) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 309.00 | 321.00 | 321.00 | 484.00 | 646.00 | 852.00 | 955.00 | 1,090 |
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income (Loss) | (9,796) | (9,436) | (8,624) | (26,808) | (10,976) | (11,603) | (11,540) | (15,404) |
| Earnings Per Share (Basic) | (1.87) | (3.32) | (3.22) | (11.29) | (4.70) | (4.98) | (4.95) | (6.61) |
| Earnings Per Share (Diluted) | (1.87) | (3.32) | (3.22) | (11.29) | (4.70) | (4.98) | (4.95) | (6.61) |
| Weighted Average Shares Outstanding (Basic) | 5,239 | 2,842 | 2,676 | 2,375 | 2,334 | 2,330 | 2,331 | 2,331 |
| Weighted Average Shares Outstanding (Diluted) | 5,239 | 2,842 | 2,676 | 2,375 | 2,334 | 2,330 | 2,331 | 2,331 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NXTC
NextCure, Inc. (NASDAQ: NXTC) is a stock listed on the Nasdaq Stock Market under the ticker symbol NXTC. It last traded at $6.78 (Nov 19, 2026, 4:00 PM ET), down 1.5% on the day. That gives NextCure a market capitalisation of $31.0M.
Over the past 52 weeks NXTC has traded between $1.55 and $15.74.
For the quarter ended Mar 31, 2026 it reported a net loss of $9.8M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$9.8M |
| Dec 31, 2025 | — | -$9.4M |
| Sep 30, 2025 | — | -$8.6M |
| Jun 30, 2025 | — | -$26.8M |
From NextCure’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…